---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336751"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2026-08-06T11:30:08+00:00"
generated_at: "2026-08-06T11:35:58.806461+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q2 2026 revenue $31.7M, IBTROZI net product revenue $23.2M; net loss $62.8M

## Summary
- Total revenue $31.7M, including $23.2M net product revenue from IBTROZI (ROS1 TKI) and $8.5M collaboration/license revenue.
- Net loss $62.8M ($0.18/share) vs $59.0M ($0.17/share) in Q2 2025; R&D spend $30.7M, SG&A $42.6M.
- Cash, equivalents, and marketable securities $661.0M as of June 30, 2026; additional $36.5M from July convertible notes overallotment.
- IBTROZI most prescribed ROS1 TKI in 2026; ~85% of ~160 new patient starts were TKI-naïve (30% QoQ growth).
- Safusidenib Phase 2 shows 51.9% ORR, median PFS not reached at 38.8 months; pivotal Phase 3 and Phase 2 studies initiated.

## SEC filing metadata
- accession: 0001193125-26-336751
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2026-08-06T11:30:08+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312526336751/0001193125-26-336751-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312526336751/d261840d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336751
- JSON: https://secwatch.observer/filing/0001193125-26-336751.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336751.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.